中华肝胆外科杂志
中華肝膽外科雜誌
중화간담외과잡지
CHINESE JOURNAL OF HEPATOBILIARY SURGERY
2010年
12期
939-942
,共4页
唐胜利%刘志苏%钱群%江从庆%艾中立
唐勝利%劉誌囌%錢群%江從慶%艾中立
당성리%류지소%전군%강종경%애중립
肝肿瘤%兔VX2%羟基磷灰石纳米粒子%瘤内注射
肝腫瘤%兔VX2%羥基燐灰石納米粒子%瘤內註射
간종류%토VX2%간기린회석납미입자%류내주사
Liver neoplasms%Rabbit VX2%Hydroxyapatite nanoparticle%Intratumoral injection
目的 研究羟基磷灰石纳米粒子瘤内注射对兔肝VX2种植瘤生长的影响.方法 将接种VX2肝肿瘤的新西兰白兔随机分成4组,每组10只.A组:肝种植瘤内注入含0.2%羧甲基纤维素钠的生理盐水1 ml;B组:注入20 mg/ml 5-Fu 1 ml;C组:注入20 mg/ml Nano-HAP溶胶1 ml;D组:注入同样浓度5-Fu和Nano-HAP混合液2 ml.四组实验动物于注药后7、14、21 d行肝脏B超扫描,记录生存时间,取肝肿瘤组织病理学检查.结果 术后7、14、21 d A组平均肿瘤体积分别为(4.93±0.76)cm3、(15.67±2.75)cm3和(52.36±10.57)cm3 ; B组为(4.16土0.33)cm3、(10.26±1.60)cm3和(18.89±4.65)cm3;C组为(1.43±0.13)cm3、(3.69±0.77)cm3和(9.51±2.09)cm3;D组为(2.80±0.46)cm3、(3.77±0.91)cm3和(8.46±0.95)cm3.B、C、D三组肿瘤体积均小于同期对照组,D组肿瘤体积最小.四组动物中位生存期分别为34、41、51和44 d.B、C、D三组生存期较对照A组延长.超声监测显示C、D组羟基磷灰石纳米粒子溶胶瘤内注射时可见肿瘤内强回声光点.多次注射后瘤体内可见钙化样强回声光团.HE染色后光镜下观察见A组和B组肿瘤组织出现多处片状坏死,C、D组注射区域呈片状坏死,被条索状或片状钙化灶分隔.结论 羟基磷灰石纳米粒子瘤内注射治疗兔VX2肝肿瘤是安全、可行的,对肿瘤生长有明显的抑制作用,未见毒性反应.
目的 研究羥基燐灰石納米粒子瘤內註射對兔肝VX2種植瘤生長的影響.方法 將接種VX2肝腫瘤的新西蘭白兔隨機分成4組,每組10隻.A組:肝種植瘤內註入含0.2%羧甲基纖維素鈉的生理鹽水1 ml;B組:註入20 mg/ml 5-Fu 1 ml;C組:註入20 mg/ml Nano-HAP溶膠1 ml;D組:註入同樣濃度5-Fu和Nano-HAP混閤液2 ml.四組實驗動物于註藥後7、14、21 d行肝髒B超掃描,記錄生存時間,取肝腫瘤組織病理學檢查.結果 術後7、14、21 d A組平均腫瘤體積分彆為(4.93±0.76)cm3、(15.67±2.75)cm3和(52.36±10.57)cm3 ; B組為(4.16土0.33)cm3、(10.26±1.60)cm3和(18.89±4.65)cm3;C組為(1.43±0.13)cm3、(3.69±0.77)cm3和(9.51±2.09)cm3;D組為(2.80±0.46)cm3、(3.77±0.91)cm3和(8.46±0.95)cm3.B、C、D三組腫瘤體積均小于同期對照組,D組腫瘤體積最小.四組動物中位生存期分彆為34、41、51和44 d.B、C、D三組生存期較對照A組延長.超聲鑑測顯示C、D組羥基燐灰石納米粒子溶膠瘤內註射時可見腫瘤內彊迴聲光點.多次註射後瘤體內可見鈣化樣彊迴聲光糰.HE染色後光鏡下觀察見A組和B組腫瘤組織齣現多處片狀壞死,C、D組註射區域呈片狀壞死,被條索狀或片狀鈣化竈分隔.結論 羥基燐灰石納米粒子瘤內註射治療兔VX2肝腫瘤是安全、可行的,對腫瘤生長有明顯的抑製作用,未見毒性反應.
목적 연구간기린회석납미입자류내주사대토간VX2충식류생장적영향.방법 장접충VX2간종류적신서란백토수궤분성4조,매조10지.A조:간충식류내주입함0.2%최갑기섬유소납적생리염수1 ml;B조:주입20 mg/ml 5-Fu 1 ml;C조:주입20 mg/ml Nano-HAP용효1 ml;D조:주입동양농도5-Fu화Nano-HAP혼합액2 ml.사조실험동물우주약후7、14、21 d행간장B초소묘,기록생존시간,취간종류조직병이학검사.결과 술후7、14、21 d A조평균종류체적분별위(4.93±0.76)cm3、(15.67±2.75)cm3화(52.36±10.57)cm3 ; B조위(4.16토0.33)cm3、(10.26±1.60)cm3화(18.89±4.65)cm3;C조위(1.43±0.13)cm3、(3.69±0.77)cm3화(9.51±2.09)cm3;D조위(2.80±0.46)cm3、(3.77±0.91)cm3화(8.46±0.95)cm3.B、C、D삼조종류체적균소우동기대조조,D조종류체적최소.사조동물중위생존기분별위34、41、51화44 d.B、C、D삼조생존기교대조A조연장.초성감측현시C、D조간기린회석납미입자용효류내주사시가견종류내강회성광점.다차주사후류체내가견개화양강회성광단.HE염색후광경하관찰견A조화B조종류조직출현다처편상배사,C、D조주사구역정편상배사,피조색상혹편상개화조분격.결론 간기린회석납미입자류내주사치료토VX2간종류시안전、가행적,대종류생장유명현적억제작용,미견독성반응.
Objective To study the inhibitory effects of hydroxyapatite nanoparticles on liver VX2 tumor in rabbits after intratumoral injection. Methods 40 rabbits with implantation of liver VX2 tumors were randomly divided into 4 groups and intratumorally injected with different preparations.Group A: (control group), 1 ml nomal saline containing 0.2% CMC-Na; Group B: ( 5-Fu group),20 mg/ml 5-Fu 1 ml; Group C: (Nano HAP), 20 mg/ml Nano HAP 1 ml; Group D: (5-Fu+Nano HAP), 20 mg/ml 5-Fu 1 ml and 20 mg/ml Nano HAP 1 ml. Ultrasonography was performed to measure liver tumor volume 7, 14, 21 d after treatment. Survival durations of the animals were recorded. Tumor tissues and liver tissues close to tumor were obtained and examined histologically.Results The average tumor volumes 7, 14 and 21 d after treatment were (4.93 ±0.76)cm3,(15. 67±2.75)cm3 and (52. 36±10. 57)cm3 in group A, (4. 16±0. 33)cm3 , (10. 26± 1.60)cm3 and (18. 89±4.65)cm3 in group B, (1.43±0.13)cm3 , (3.69±0.77)cm3 and (9.51±2.09)cm3 in group C, (2. 80±0.46)cm3 , (3. 77±0. 91)cm3 and (8. 46±0.95)cm3 in group D respectively. The average tumor volumes of groups B, C and D were significantly smaller than that of group A in the same time phases after treatment. The life span of group C was longer than that of other three groups, and there was no statistically significant difference between group B and group D, although the two groups were significantly longer than group A. Blood flow was not detected by color Doppler or power Doppler in group C and group D. Pathological examination showed that there was obvious intratumoral necrosis in group C and D. Tumor in group B exhibited thoroughgoing necrosis. Conclusion Hydroxyapatite nanoparticles intratumoral injection is safe and feasible for treatment of liver tumor. Hydroxyapatite nanoparticles can exert a significant inhibitory effect on liver VX2 tumor growth in rabbits without liver toxicity.